TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MLE4901 vs. Placebo for the Treatment of PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Oligo-/amenorrhea~2. At least one of the following during Screening:~   * Clinical signs of hyperandrogenism, where clinical hyperandrogenism may include hirsutism (defined as excessive terminal hair that appears in a male pattern), acne, or androgenic alopecia~  * Biochemical hyperandrogenism refers to an elevated serum androgen level (i.e., total, bioavailable or free testosterone level ≥ULN)~  * Polycystic ovarian morphology, defined as the presence of 12 or more follicles 2-9 mm in diameter and/or an increased ovarian volume \>10 mL (without a cyst or dominant follicle) in either ovary~3. Body mass index (BMI) 22 to 45 kg/m2, inclusive~4. Must be willing to avoid use of all hair removal procedures and products during study participation~5. Must be willing to avoid all prescription treatments for acne and not increase the dose or frequency of their current non-prescription acne treatment regimen during study participation~6. Must be willing to avoid the use of all hair growth procedures and products during study participation~7. Permanently surgically sterilized (bilateral salpingectomy or tubal occlusion) \>2 years or male partner(s) has had a vasectomy \>2 years or must consent to use two permitted medically-acceptable methods of contraception throughout the study during any sexual intercourse with a male partner. Permitted medically-acceptable methods of birth control for this study are defined as use of a male condom plus one of the following: spermicide, diaphragm with spermicide, or an intrauterine device that does not contain steroid hormones.~Exclusion Criteria:~1. Menopausal or peri-menopausal, defined for this study as FSH (follicle stimulating hormone ) \>10 IU/L~2. Irregular vaginal/menstrual bleeding caused by conditions other than PCOS (e.g., uterine polyps or submucosal uterine fibroids)~3. Abnormal Papanicolaou (Pap) test during Screening requiring follow-up sooner than 1 year after the test~4. Uncontrolled hypo- or hyperthyroidism~5. Post-hysterectomy or endometrial ablation~6. Post-oophorectomy (unilateral or bilateral) or other ovarian surgery~7. Medical history of type 1 or type 2 diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
- MLE4901 (Type: EXPERIMENTAL): Plain, round, biconvex, white film-coated tablets administered twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Preemptive Volume Loading to Prevent Arterial Hypotension During Induction of General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients undergoing elective surgery.~Exclusion Criteria:~* Difficult peripheral venous access~* Allergy to gelatin~* Symptomatic cardiac disease, rhythm trouble, pace-maker, aortic valvular disease, aortic disease~* Morbid obesity, low BMI,~* hypovolemia,~* Raynaud syndrome or scleroderma,~* Contra-indication to propofol, remifentanil or to the use of Bispectral Index,~* Hematocrit \< 20%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High pre-emptive volume loading (Type: EXPERIMENTAL): None
- Low pre-emptive volume loading (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men or women, aged 18 years or older~* Voluntarily signed up for a sport event or to run a marathon or a half marathon for the first time~* Normal to mildly elevated blood pressure (systolic blood pressure \< 140 mmHg and/or diastolic blood pressure \< 90 mmHg)~* Hormone replacement therapy and birth control pills are allowed, provided they have been on a stable dose for more than 3 months and no change in dose is planned for the duration of the study~* Capable and willing to provide written, informed consent for the study~Exclusion Criteria:~* History of cardiovascular disease within the past year (cardiomyopathy, heart failure, ischemic heart disease, stroke, TIA, peripheral vascular disease)~* Change in body weight more than 10% over the past year~* History of significant medical conditions, including respiratory, gastrointestinal, neuromuscular, neurological or musculoskeletal problems interfering with exercise.~* Autoimmune or collagen vascular diseases, chronic anemia,~* Malignancies in the past 5 years, with the exception of treated skin or breast cancer that did not require treatment with chemotherapy.~* Diabetes~* Pregnancy or recent delivery: delivery date less than 3 months prior to enrollment~* Lipid lowering medications (statins, niacin, resins) are allowed, provided dose has not changed for 3 months prior to enrollment and is not anticipated to change during the study~* Fish Oil supplements are allowed, provided dose has been unchanged for 3 months prior to enrollment and no change in dose is planned for the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exercise training, women, marathon. (Type: None): Other: prospective study with no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Successful completion of AVA102670 or AVA102672 without safety or tolerability issues. Regular caregiver.~Exclusion criteria:~* Congestive Heart Failure (NYHA 1-4), clinically significant peripheral edema, other neurological conditions that might disqualify participation. SAE, clinically significant laboratory abnormality or significant cardiovascular event during prior study.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: 91 Years
- Healthy Volunteers: f

Study Arms:
- Rosiglitazone XR (Type: EXPERIMENTAL): Investigational drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Nitrous Oxide Analgesia Vaso-occlusive Crisis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with sickle cell disease~* Ages 8 to 18, inclusive~* Present to the pediatric emergency department with VOC and whose pain scores remain greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV fluids, morphine and NSAIDs).~Exclusion Criteria:~* life-threatening illness as determined by attending clinician~* developmental delay~* altered level of consciousness~* any contraindications to receiving N2O~* foster children and wards of the state

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Nitrous oxide 50% (Type: EXPERIMENTAL): Nitrous oxide 50% administered for 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine in Women With Operable Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of primary invasive breast cancer~* Stage I-III operable breast cancer.~* Primary tumor must be greater than or equal to 2cm by radiographic imaging or palpitation~* Women greater than 18 years of age~* ECOG performance status 0-1~* WBC \> 4000/mm3~* Platelet count \> 100,000/mm3~* SGOT \< 2x ULN~* Calculated creatinine clearance \> 50ml/min~Exclusion Criteria:~* Evidence of metastatic (stage IV) cancer on physical exam or any diagnostic study.~* Pregnant or breast-feeding women~* Inflammatory breast cancer~* HER2 positive disease~* History of hypersensitivity to a 5-FU or known dihydropyrimidine dehydrogenase (DPD) deficiency~* Uncontrolled intercurrent illness~* Prior history of breast cancer are ineligible except: diagnosed at least 2 years ago; present cancer is not in previously irradiated breast; no prior chemotherapy in the past 5 years; no prior high-dose chemotherapy with stem cell or bone marrow transplant.~* Excisional biopsy performed prior to enrollment~* Uncontrolled coagulopathy~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of the Erigo Machine on Functional Recovery in ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Admission to Trauma ICU~1. Trauma Patients requiring physical therapy (including severe traumatic brain injury or polytrauma without extremity fractures or unstable thoracic or lumbar spine fracture~2. Burn patients requiring physical therapy~3. GI surgery patients requiring physical therapy~4. Necrotizing fasciitis patient requiring physical therapy~Exclusion Criteria:~Patients with the following conditions:~1. Non-weight bearing on lower extremities~2. Untreated DVT~3. Active hemorrhage~4. Leg length \>102cm or \<72cm~5. Weight \>135kg~6. Systolic BP \> 20mmHg sustained for 10min~7. Heart rate \>20bpm outside goal for more than 20min~8. Intracranial pressure (ICP) \>20mmHg sustained for 10min if applicable,~9. Temperature \>38.2C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erigo Pro plus standard Physical Therapy (Type: EXPERIMENTAL): The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
- Standard Physical Therapy (Type: ACTIVE_COMPARATOR): Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent before any trial-related activity is performed~* Has a confirmed prostate cancer in which this type of treatment is needed.~Exclusion Criteria:~* Previous treatment for prostate cancer~* Previous trans-urethral resection of the prostate~* Current use of 5-alpha reductase inhibitor or α-adrenoceptor antagonist.~* Patients in need of external beam radiotherapy to be started at the same time as hormone therapy~* Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)~* History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.~* Hypersensitivity towards any component of the investigational product~* Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.~* Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): Goserelin (3.6 mg) + bicalutamide (50 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anterior Ligament Rupture With Internal Brace Repair - A Prospective Randomised Controlled Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anterior cruciate ligament rupture~Exclusion Criteria:~* Current malignant disease~* Rheumatoid arthritis~* Other knee ligament instability~* Obesity BMI \>30~* Morbus Bechterew

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Repair (Type: EXPERIMENTAL): Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
- Patella tendon graft (Type: ACTIVE_COMPARATOR): The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-documented, newly-diagnosed primary cervical cancer of all histopathology types.~* Clinically visible gross lesion (International Federation of Gynecology and Obstetrics (FIGO) stage IB1 and above).~* Treatment (chemoradiation), DCE-MRI and 18F-FMISO PET studies will be at MSKCC.~* Patients must be an adult female 18 years of age or older.~Exclusion Criteria:~* Patients who because of general medical or psychiatric condition, or physiologic status cannot give an informed consent.~* Patients who received prior radiation treatment to pelvis.~* Patients with contraindications to DCE-MRI (non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium, end-stage renal disease) and/or 18F-FMISO PET.~* Patients who do not fulfill the screening criteria for safe DCE-MRI or 18F-FMISO PET as per the Department of Radiology guidelines.~* Pregnant patients; and or patients who are breast-feeding their babies.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCE-MRI and 18F-FMISO PET (Type: EXPERIMENTAL): Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ear Acupuncture for Acute Sore Throat in Patients Unable to Take Non-steroidal Anti-inflammatory Agents (NSAIDs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Male and female subjects (DoD beneficiaries), 18 years or older, with upper respiratory complaints and their primary symptom being acute sore throat.~* Minimum pain score of 5 points on a 11 point scale (0-10 with 10 being the worst pain)~The above with any one of the following:~* Allergy to Non-Steroidal Anti-inflammatory agents (NSAIDs)~* History of significant gastrointestinal bleed~* Previous documented history of stage 2 kidney disease or worse~* History of gastric bypass surgery~* Chronic oral steroids use~Exclusion:~* Absence of one or more ears~* Known Pregnancy~* Known Peritonsillar abscess (PTA)~* Throat, mouth or esophageal cancer~* Active cellulitis of ear~* Ear anatomy precluding identification of acupuncture landmarks~* Use of Hearing Aids that preclude the use of ear acupuncture~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- battlefield auricular acupuncture (Type: EXPERIMENTAL): None
- placebo (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85~* Clinical appearance of lesion~  * Homogenous leukoplakia~ * Non- homogenous leukoplakia~ * Erythroplakia~ * Proliferative verrucous leukoplakia~* Histologic appearance~  * No dysplasia~ * Mild dysplasia~ * Moderate dysplasia~ * Severe dysplasia~* Diabetics: if on metformin, will get them to 2000 mg per day, if not, will add metformin in consultation with endocrinologist~* All subjects must be able to comprehend and sign a written informed consent document~* Willing and able to be available for the duration of the study~* In general good health with no contraindication to biopsy or metformin therapy~* Laboratory results~Exclusion Criteria:~* Carcinoma in-situ, verrucous carcinoma, invasive squamous cell carcinoma (SCCa)~* Exclude systemic causes of the lesion: pemphigus, pemphigoid, systemic lupus erythematosus (SLE), lichenoid drug reaction, human immunodeficiency virus (HIV), syphilis~* Exclude local inciting factors: rule out (r/o) but allowing 2 weeks to pass and see if there is resolution, if not and doesn't resolve with local measures, medical treatment, enroll~  * Frictional: sharp tooth~ * Trauma~* Immunosuppression by natural illness or medically induced~* Hypersensitivity or allergic reaction to metformin or some other contraindication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Prevention (metformin) (Type: EXPERIMENTAL): Patients receive metformin PO QD on days 1-3 and then PO BID for up to 12 months in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. HIV- men and women, age 18 and higher, who are seeking PrEP and deemed appropriate per local site investigator following the CDC risk indication guidelines for PrEP.~2. Must fit into one of the study's CDC-identified risk strata: a) IDUs and/or b) Caucasian LGBTQ or Minority LGBTQ~3. Must be able to read and write English for themselves.~Exclusion Criteria~1. Same as that for PrEP initiation, e.g., existing HIV+ diagnosis or contra-indications, creatinine GFR \< 60.~2. Current or previous use of PrEP.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Future Self - Value Affirmation (Type: EXPERIMENTAL): This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
- Control (Type: SHAM_COMPARATOR): In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues